Previous 10 | Next 10 |
ObsEva (OBSV): Q3 GAAP EPS of -$0.49 misses by $0.16.Cash and cash equivalents at September 30, 2020 to $50.6M.Press Release For further details see: ObsEva EPS misses by $0.16
Positive Phase 3 PRIMROSE 1 and 2 trial results of linzagolix for the treatment of heavy menstrual bleeding due to uterine fibroids presented in late breaking session of ASRM Virtual Congress Linzagolix regulatory submissions planned for Q4:20/H1:21 in Europe/U.S. ...
DBV Technologies S.A. (DBVT) +80% as EMA approves Viaskin Peanut application.Endurance International Group Holdings (EIGI) +61% on announcing agreement to be acquired by Clearlake Capital Group L.P.AnPac Bio-Medical Science (ANPC) +30% as its Chinese company secu...
Geneva, Switzerland and Boston, MA – 2 November, 2020 – ObsEva SA (NASDAQ: OBSV / SIX: OBSN), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced an oral communication and ...
Geneva, Switzerland and Boston, MA – October 22, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of two posters at...
Geneva, Switzerland and Boston, MA – October 20, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced the presentation of a poster at th...
Geneva, Switzerland and Boston, MA – September 8, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that CEO Ernest Loumaye ...
DPW Holdings (NYSEMKT: DPW ) +45% on expecting initial orders for electric vehicle charger product line in Q4. More news on: DPW Holdings, Inc., I-Mab, AnPac Bio-Medical Science Co., Ltd., Stocks on the move, , Read more ...
ObsEva (NASDAQ: OBSV ) is up 1.8% in after-hours trading after it announced the pricing of an underwritten equity offering and concurrent private placement transaction. More news on: ObsEva SA, , Healthcare stocks news, Stocks on the move, Read more ...
GENEVA, Switzerland and BOSTON, MA (September 3, 2020) – ObsEva SA (NASDAQ: OBSV) (SIX: OBSN) (“ObsEva” or the “Company”), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reprod...
News, Short Squeeze, Breakout and More Instantly...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – April 3, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that the Regulatory ...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange GENEVA, Switzerland – March 18, 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing and commercializing novel therapies for women’s health, today announced that, concurr...
Ad hoc announcement pursuant to Art. 53 LR of the SIX Swiss Exchange Geneva, Switzerland – 28 February 2024 – ObsEva SA (SIX: OBSN), a biopharmaceutical company developing novel therapies for women's health, today announced that it will wind-down its operati...